cm-cs1 t-cell
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02203825)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - nkg2d
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cm-cs1 t-cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02203825 | Phase 1 | Mar 1, 2015 | Celyad, Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celyad | For profit | 1 | 1 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1